VivoSeq
Oncology

Iris Melanoma

5

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Iris Melanoma is an early-stage landscape with 5 programs across 5 companies. The most active players are Eli Lilly, Regeneron, Sanofi. 1 therapy is approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 3E

Eastern Cooperative Oncology Group

1 program

Phase 3C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

5programs
Protein / enzyme240%
Small molecule120%
Monoclonal antibody120%
Peptide120%

Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

1

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma
Completed·National Cancer Institute (NCI)·Phase 3·NCT01989572·815 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)